(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Outlook Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast OTLK's revenue for 2025 to be $215,640,980, with the lowest OTLK revenue forecast at $57,065,639, and the highest OTLK revenue forecast at $421,815,777. On average, 4 Wall Street analysts forecast OTLK's revenue for 2026 to be $1,062,830,744, with the lowest OTLK revenue forecast at $574,013,193, and the highest OTLK revenue forecast at $1,710,290,772.
In 2027, OTLK is forecast to generate $3,589,898,652 in revenue, with the lowest revenue forecast at $3,280,569,320 and the highest revenue forecast at $3,899,261,552.